جمعه 22 آبان 1405
[Archive]
پذیرفته شده و در حال انتشار
برگشت به فهرست مقالات |
برگشت به فهرست نسخه ها
Ethics code: IR.TABRIZU.REC.1403.113
چکیده: (765 مشاهده)
Background: Colorectal cancer (CRC) is a common and multifactorial malignancy influenced by both genetic and environmental factors. Long non-coding RNAs (lncRNAs) have emerged as important regulators of tumor initiation and progression. Previous studies have linked HNF1A-AS1 and MCM3AP-AS1 expression to clinicopathological features in several cancers. This case–control study aimed to evaluate the expression levels of these lncRNAs in CRC tissues before and after chemotherapy with capecitabine and celecoxib, compared with non-cancerous control tissues.
Methods: Tissue samples were collected from 98 CRC patients before and after chemotherapy and from 71 non-cancerous controls obtained during colonoscopy or surgery. Total RNA was extracted, reverse transcribed into cDNA, and gene expression levels were quantified using real-time quantitative PCR.
Results: Both HNF1A-AS1 and MCM3AP-AS1 were significantly upregulated in CRC tissues before treatment compared with controls (p = 0.0051 and p = 0.0393, respectively). However, no significant differences in expression were observed between pre- and post-treatment samples (p > 0.05). ROC curve analysis revealed weak diagnostic performance for each lncRNA individually, whereas their combined analysis showed modest diagnostic value (AUC = 0.66). Chemotherapy was associated with an improvement in mean patient survival of approximately 16 months.
Conclusion: Chemotherapy with capecitabine and celecoxib did not significantly alter the expression of HNF1A-AS1 or MCM3AP-AS1 in CRC patients, despite improved survival outcomes. The combined assessment of these lncRNAs may have limited diagnostic utility, but they do not appear to be suitable biomarkers for monitoring chemotherapy response.
Methods: Tissue samples were collected from 98 CRC patients before and after chemotherapy and from 71 non-cancerous controls obtained during colonoscopy or surgery. Total RNA was extracted, reverse transcribed into cDNA, and gene expression levels were quantified using real-time quantitative PCR.
Results: Both HNF1A-AS1 and MCM3AP-AS1 were significantly upregulated in CRC tissues before treatment compared with controls (p = 0.0051 and p = 0.0393, respectively). However, no significant differences in expression were observed between pre- and post-treatment samples (p > 0.05). ROC curve analysis revealed weak diagnostic performance for each lncRNA individually, whereas their combined analysis showed modest diagnostic value (AUC = 0.66). Chemotherapy was associated with an improvement in mean patient survival of approximately 16 months.
Conclusion: Chemotherapy with capecitabine and celecoxib did not significantly alter the expression of HNF1A-AS1 or MCM3AP-AS1 in CRC patients, despite improved survival outcomes. The combined assessment of these lncRNAs may have limited diagnostic utility, but they do not appear to be suitable biomarkers for monitoring chemotherapy response.
فهرست منابع
1. Wong MC, Huang J, Lok V, Wang J, Fung F, Ding H, et al. Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin Gastroenterol Hepatol. 2021;19(5):955-966.e61. [DOI:10.1016/j.cgh.2020.02.026] [PMID]
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]
3. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145-164. [DOI:10.3322/caac.21601] [PMID] [PMCID]
4. Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). 2022;14(7):1732. [DOI:10.3390/cancers14071732] [PMID] [PMCID]
5. Pickhardt PJ, Kim DH, Pooler BD, Hinshaw JL, Barlow D, Jensen D, et al. Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history. Lancet Oncol. 2013;14(8):711-720. [DOI:10.1016/S1470-2045(13)70216-X] [PMID] [PMCID]
6. Beilankouhi EAV, Sajadi MA, Alipourfard I, Hassani P, Valilo M, Safaralizadeh R. Role of the ER-induced UPR pathway, apoptosis, and autophagy in colorectal cancer. Pathol Res Pract. 2023;248:154706. [DOI:10.1016/j.prp.2023.154706] [PMID]
7. Wu J, Meng X, Jia Y, Chai J, Wang J, Xue X, et al. Long non-coding RNA HNF1A-AS1 upregulates OTX1 to enhance angiogenesis in colon cancer via the binding of transcription factor PBX3. Exp Cell Res. 2020;393(2):112025. [DOI:10.1016/j.yexcr.2020.112025] [PMID]
8. Liu J, Guo B. RNA-based therapeutics for colorectal cancer: updates and future directions. Pharmacol Res. 2020;152:104550. [DOI:10.1016/j.phrs.2019.104550] [PMID] [PMCID]
9. Nazari Soltan Ahmad S, Kalantary-Charvadeh A, Hamzavi M, Ezzatifar F, Aboutalebi Vand Beilankouhi E, Toofani-Milani A, et al. TGF-β1 receptor blockade attenuates unilateral ureteral obstruction-induced renal fibrosis in C57BL/6 mice through attenuating Smad and MAPK pathways. J Mol Histol. 2022;53(4):691-698. [DOI:10.1007/s10735-022-10078-6] [PMID]
10. Pouya FD, Rasmi Y, Camci IY, Tutar Y, Nemati M. Performance of capecitabine in novel combination therapies in colorectal cancer. J Chemother. 2021;33(6):375-389. [DOI:10.1080/1120009X.2021.1920247] [PMID]
11. Jin KT, Yao JY, Fang XL, Di H, Ma YY. Roles of lncRNAs in cancer: focusing on angiogenesis. Life Sci. 2020;252:117647. [DOI:10.1016/j.lfs.2020.117647] [PMID]
12. Tang X, Qiao X, Chen C, Liu Y, Zhu J, Liu J. Regulation mechanism of long noncoding RNAs in colon cancer development and progression. Yonsei Med J. 2019;60(4):319-325. [DOI:10.3349/ymj.2019.60.4.319] [PMID] [PMCID]
13. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, et al. Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014;24(5):513-531. [DOI:10.1038/cr.2014.35] [PMID]
14. Javed Z, Khan K, Sadia H, Raza S, Salehi B, Sharifi-Rad J, et al. LncRNA & Wnt signaling in colorectal cancer. Cancer Cell Int. 2020;20:326. [DOI:10.1186/s12935-020-01412-7] [PMID] [PMCID]
15. Zoldoš V, Horvat T, Novokmet M, Cuenin C, Mužinić A, Pučić M, et al. Epigenetic silencing of HNF1A associates with changes in the composition of the human plasma N-glycome. Epigenetics. 2012;7(2):164-172. [DOI:10.4161/epi.7.2.18918] [PMID] [PMCID]
16. Zhang Y, Shi J, Luo J, Liu C, Zhu L. Regulatory mechanisms and potential medical applications of HNF1A-AS1 in cancers. Am J Transl Res. 2022;14(6):4154.
17. Zhou X, Fan YH, Wang Y, Liu Y. Prognostic and clinical significance of long non-coding RNA HNF1A-AS1 in solid cancers: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(49):e18264. [DOI:10.1097/MD.0000000000018264] [PMID] [PMCID]
18. Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019;18(1):1-16. [DOI:10.1186/s12943-024-02122-8]
19. Yu X, Zheng Q, Zhang Q, Zhang S, He Y, Guo W. MCM3AP-AS1: an indispensable cancer-related lncRNA. Front Cell Dev Biol. 2021;9:752718. [DOI:10.3389/fcell.2021.752718] [PMID] [PMCID]
20. Zhang X, Xiong Y, Tang F, Bian Y, Chen Y, Zhang F. Long noncoding RNA HNF1A-AS1 indicates a poor prognosis of colorectal cancer and promotes carcinogenesis via activation of the Wnt/β-catenin signaling pathway. Biomed Pharmacother. 2017;96:877-883. [DOI:10.1016/j.biopha.2017.10.033] [PMID]
21. Zhang J, Li K, Zheng H, Zhu Y. Research progress review on long non-coding RNA in colorectal cancer. Neoplasma. 2021;68(2):240-252. [DOI:10.4149/neo_2020_201012N1073] [PMID]
22. Liu CG, Li J, Xu Y, Li W, Fang SX, Zhang Q, et al. Long non-coding RNAs and circular RNAs in tumor angiogenesis: from mechanisms to clinical significance. Mol Ther Oncolytics. 2021;22:336-354. [DOI:10.1016/j.omto.2021.07.001] [PMID] [PMCID]
23. Fu L, Zhang G, Wang Y, Lu T, Liu B, Jiao Y, et al. The prognostic value of lncRNA MCM3AP-AS1 on clinical outcomes in various cancers: a meta- and bioinformatics analysis. Dis Markers. 2022;2022:4466776. [DOI:10.1155/2022/4466776] [PMID] [PMCID]
24. Song Q, Gao J, Yang J, Gopinath SC, Shen L. Prognostic analysis of lncRNA MCM3AP-AS1 in colorectal cancer and the mechanism of its effect on tumor cell activity. Biomed Res Int. 2022;2022:1616370. [DOI:10.1155/2022/1616370] [PMID] [PMCID]
25. Dai W, Zeng W, Lee D. lncRNA MCM3AP-AS1 inhibits the progression of colorectal cancer via the miR-19a-3p/FOXF2 axis. J Gene Med. 2021;23(3):e3306 [DOI:10.1002/jgm.3306] [PMID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
